NCT06448364View on ClinicalTrials.gov

A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination

PHASE1TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

May 9, 2024

Primary Completion Date

August 15, 2024

Study Completion Date

August 15, 2024

Conditions
Advanced or Metastatic Solid TumorsNon-Small Cell Lung CancerColorectal CancerUrothelial CancerMelanoma
Interventions
BIOLOGICAL

PF-07329640

an anti-lymphotoxin beta receptor agonist

BIOLOGICAL

sasanlimab

A monoclonal antibody that blocks the interaction between PD-1 and PD-L1/L2

BIOLOGICAL

bevacizumab

a monoclonal antibody that blocks VEGF

Trial Locations (7)

72703

Highlands Oncology, Fayetteville

72758

Highlands Oncology, Rogers

72762

Highlands Oncology Group, Springdale

78229

NEXT Oncology, San Antonio

00935

Hospital Oncológico Dr. Isaac González-Martinez, Rio Piedras

Pan American Center for Oncology Trials, LLC, Rio Piedras

Pan American Center for Oncology Trials- Hospital Oncologico, Rio Piedras

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT06448364 - A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination | Biotech Hunter | Biotech Hunter